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Abstract

Author Manuscript

Comorbid physical and mental health problems are associated with poorer substance abuse
treatment outcomes; however, little is known about these conditions among stimulant abusers at
treatment entry. This study compared racial and ethnic groups on baseline measures of drug use
patterns, comorbid physical and mental health disorders, quality of life, and daily functioning
among cocaine and stimulant abusing/dependent patients. Baseline data from a multi-site
randomized clinical trial of vigorous exercise as a treatment strategy for a diverse population of
stimulant abusers (N = 290) were analyzed. Significant differences between groups were found on
drug use characteristics, stimulant use disorders, and comorbid mental and physical health
conditions. Findings highlight the importance of integrating health and mental health services into
substance abuse treatment and could help identify potential areas for intervention to improve
treatment outcomes for racial and ethnic minority groups.
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INTRODUCTION
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U.S. population surveys and treatment studies indicate there are racial and ethnic differences
in the prevalence of substance use and participation in substance abuse treatment (Substance
Abuse and Mental Health Services Administration, 2008, 2010). The National Institute on
Drug Abuse (NIDA) reports that racial and ethnic minorities comprise 40% of admissions to
publicly funded substance abuse treatment programs (National Institue on Drug Abuse,
2011). Recent research suggests these populations may be at particular risk for poor
treatment outcomes, largely due to socioeconomic factors (Saloner & Le Cook, 2013).
Despite well-described difficulties in fulfilling the National Institutes of Health’s required
inclusion of racial and ethnic minorities in the design and conduct of clinical trials (Arean,
Alvidrez, Nery, Estes, & Linkins, 2003; Yancey, Ortega, & Kumanyika, 2006), the NIDA
Clinical Trials Network (CTN) has continually demonstrated success in the recruitment and
retention of these populations (Burlew et al., 2011; Carroll et al., 2007). As such, the CTN
offers a unique opportunity to better characterize racial and ethnic minorities in treatment
and detect differences in the needs of underserved populations. In particular, this study
examined racial and ethnic differences in the physical and mental health conditions often
comorbid with stimulant abuse/dependence.

Author Manuscript

Previous evidence from the CTN shows marked heterogeneity in diagnosed stimulant users,
with differences in use patterns and subtypes among racial and ethnic minorities (Wu et al.,
2009). In one multisite study of treatment-seeking adults, most stimulant users were Black
and used cocaine only, whereas primary amphetamine users were more likely to be White or
Hispanic. In fact, there were no Black participants among amphetamine users in the study.
In addition, amphetamine users were more likely than cocaine users to be court-ordered to
treatment and to be on probation or parole (Wu et al., 2009).
Comorbid Physical Health Conditions

Author Manuscript

Among patients seeking treatment for substance abuse, the comorbid medical illness burden
is far greater than for the general population, possibly due to lack of access to primary care
(De Alba, Samet, & Saitz, 2004). In addition, there is significant evidence that racial and
ethnic minority populations are generally less likely to receive a variety of medical services.
These disparities hold even when controlling for insurance status, income, age, and
education level (Institute of Medicine, 2003) and are amplified in the presence of substance
abuse and comorbid psychiatric disorders (De Alba et al., 2004; Druss & von Esenwein,
2006). Anywhere from 45% to 70% of people with drug addictions report having at least
one chronic medical illness (Chang et al., 2010) and many people have poly-substance
dependence resulting in combined risks for multiple medical illnesses (Wadland &
Ferenchick, 2004). Comorbid mental health disorders and physical health problems
negatively affect treatment outcomes via early dropout and relapse (Compton, Cottler,
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Jacobs, Ben-Abdallah, & Spitznagel, 2003; Druss & von Esenwein, 2006; Kessler et al.,
2003).
Comorbid Mental Health Conditions

Author Manuscript

The presence of mental health disorders in the context of substance dependence is associated
with greater illness severity and substantial disability (Compton et al., 2003; Compton,
Thomas, Stinson, & Grant, 2007; L. Davis et al., 2012; Nunes & Levin, 2004). Individuals
with substance use disorders endorse greater depression symptom severity, length of illness,
likelihood of anxious features, and worse remission/response outcomes with treatment
(Compton et al., 2007; K. Davis, Schoenbaum, & Audet, 2005). Major depression predicts a
greater number of substances used, and alcohol dependence and generalized anxiety disorder
both predict higher rates of drug dependence diagnoses (Compton et al., 2003). The
physical, mental, and legal consequences of drug use are far greater for racial and ethnic
minorities, and the presence of multiple disorders at baseline predicts worse substance abuse
treatment outcomes (Burlew, Feaster, Brecht, & Hubbard, 2009).
The Current Study

Author Manuscript

The current study compared racial and ethnic groups on baseline measures of drug use
patterns, comorbid physical and mental health disorders, quality of life, and daily
functioning among participants in the Stimulant Reduction Intervention using Dosed
Exercise (CTN-0037) trial, a multisite randomized clinical trial implemented through the
NIDA’s National Drug Abuse Treatment CTN. The trial aimed to test a novel approach to
the treatment of stimulant abuse via the addition of vigorous exercise compared to health
education as a treatment strategy for stimulant abuse or dependence (Trivedi, Greer, et al.,
2011). CTN-0037 hypothesized that exercise has the potential to improve other health
domains that might be adversely affected by stimulant use or its treatment, such as sleep
disturbance, cognitive function, mood, weight gain, quality of life, and anhedonia.
For the current study, we hypothesized that racial and ethnic groups would use different
substances and report different patterns of drug use resulting in different rates of stimulant
use disorder diagnosis. We also expected the presence of comorbid mental health diagnoses
to be more prevalent and severity of depression to be greater among racial and ethnic
minority populations and to correspond with poor physical health functioning and quality of
life in this sample of stimulant abusing/dependent patients in residential treatment.

METHODS
Author Manuscript

Study Sample and Procedures
Participants were recruited from 9 geographically diverse, community-based substance
abuse treatment programs across the United States and were enrolled in the multi-site
Stimulant Reduction Intervention using Dosed Exercise (CTN-0037) trial within the NIDA
National Drug Abuse Treatment CTN. The NIDA CTN framework consists of 13 research
nodes across the United States that partner with a variety of community-based treatment
programs. The CTN provides a broad infrastructure for rapid, multisite testing of promising
science-based therapies and the subsequent delivery of these treatments to patients in
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community-based treatment. Details of the study rationale and design have been previously
published (Trivedi, Greer, et al., 2011). The study was reviewed and approved by the
Institutional Review Board (IRB) at University of Texas Southwestern Medical Center, as
well as the IRBs of each of the participating treatment programs. All participants provided
written informed consent.

Author Manuscript

Trial site selection criteria were broad, with the goal of testing the intervention in a wide
range of outpatient substance abuse populations, and geographic location was an important
consideration in enhancing representation in the trial. Selected sites had a residential
component and length of stay generally between 21 and 30 days. Other site characteristics
included a requirement of no formal exercise program as a component of treatment and
availability of outpatient treatment at or near the residential setting where the study was
located so that it was feasible for participants to return to the study site to complete study
activities for the full 9 months of the study (Trivedi, Greer, et al., 2011; Warden et al.,
2012).
Eligible participants were those reporting illicit stimulant drug use (e.g., cocaine,
methamphetamine, or amphetamine) within the 30 days prior to admission to residential
treatment and who received medical clearance for exercise through a protocol-defined
maximal exercise test (in accordance with American College of Sports Medicine (2010)
guidelines), medical history, and physical examination from protocol-approved medical
personnel. Participants with general medical conditions that contraindicated exercise and
those with psychosis or other psychiatric conditions that posed a safety risk were excluded
(Trivedi, Greer, et al., 2011).

Author Manuscript

This analysis included data collected during the baseline evaluation (N = 290) for
participants who self-identified as non-Hispanic Black (n = 128), non-Hispanic White (n =
131), or Hispanic (n = 31). Individuals identifying multiple races (n = 8) or “other” (n = 4)
were too few to analyze and were excluded. Recruited individuals were diagnosed with
stimulant abuse or dependence (i.e., cocaine, methamphetamine, amphetamine or other
stimulant, except caffeine or nicotine) as defined by Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) (American Psychiatric
Association, 2000). Those with opioid dependence were excluded from participation.
Eligible participants were randomized to one of two treatment arms: vigorous intensity high
dose exercise augmentation or health education intervention augmentation. The CTN-0037
study design has been described in detail elsewhere (Trivedi, Greer, et al., 2011).
Measures

Author Manuscript

Demographics—Standard demographic information collected included gender, race,
ethnicity, and education.
Diagnostic assessments—Stimulant use disorders were assessed using the substance
use modules from the World Health Organization (WHO) Composite International
Diagnostic Interview (CIDI) (Version 2.1) for DSM-IV-TR stimulant abuse and dependence
(Robins et al., 1988; WHO, 1997). Diagnostic categories required for study entry included
one or more of the following: cocaine abuse, cocaine dependence, other stimulant abuse, and
J Ethn Subst Abuse. Author manuscript; available in PMC 2016 January 12.
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other stimulant dependence. Because several participants received more than one diagnosis,
the sample was grouped into the following categories to collapse the abuse/dependence
differentiation and better reflect the substance(s) used, as follows: cocaine use disorder only,
cocaine plus other stimulant use disorder (e.g., methamphetamine), and other stimulant use
disorder only.
The Mini International Neuropsychiatric Interview (MINI) (Sheehan et al., 1997) was used
to obtain diagnostic information for other DSM-IV-TR Axis I disorders. The total number of
current psychiatric disorders was summed for each participant (range, 0–13). Nicotine
dependence among smokers was evaluated using the Fagerström Test for Nicotine
Dependence, a 6-item questionnaire with a total score range of 0 to 10, with higher scores
indicating greater nicotine dependence (Heatherton, Kozlowski, Frecker, & Fagerstrom,
1999; Kozlowski, Porter, Orleans, Pope, & Heatherton, 1994).

Author Manuscript

Drug use—Drug, alcohol, and nicotine quantity and frequency were assessed for the 30
days prior to residential treatment admission using the Timeline Followback method (Sobell
& Sobell, 1992). The Addiction Severity Index-Lite assessed multiple domains commonly
affected by substance use, including medical, employment/self-support, alcohol use, drug
use, legal status, family/social, and psychiatric status (McLellan, Luborsky, Woody, &
O’Brien, 1980).

Author Manuscript

Mental health and well being—Risk for suicide and related behaviors was evaluated
using the Concise Health Risk Tracking–Self-Report, a 14-item participant self-report
assessment with item responses ranging from 0 (strongly disagree) to 4 (strongly agree)
(Trivedi, Wisniewski, et al., 2011). A propensity score is derived by summing items 1 to 11,
resulting in a range of 0 to 44. A risk score is derived by summing items 12 to 14, resulting
in a range of 0 to 12.
The Short-Form Health Survey (SF-36) was used to assess quality of life and general health
(Ware, 2003). The SF-36 contains eight subscales measuring the following domains:
Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social
Functioning, Role-Emotional, and Mental Health. Subscale scores range from 0 to 100, with
higher scores indicating better perceived health and functioning. The Mental Health Status
component score is a weighted average of all of the subscale scores, with the Vitality, Social
Functioning, Role-Emotional, and Mental Health subscales contributing the most.

Author Manuscript

The Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Endicott, Nee,
Harrison, & Blumenthal, 1993) was used to examine participants’ general quality of life.
Participants rated their satisfaction with the following domains of activity: physical health,
feelings, work, household duties, school/course work, leisure time activities, and social
relations. Each item uses a 5-point scale ranging from 1 (very poor) to 5 (very good). The
raw total score (possible range from 14 to 70) was transformed into a percentage maximum
possible score with a possible range of 0 to 100. Higher scores indicate greater life
satisfaction and enjoyment.

J Ethn Subst Abuse. Author manuscript; available in PMC 2016 January 12.

Sanchez et al.

Page 6

Author Manuscript

Physical health—Participants completed the Self-Administered Comorbidity
Questionnaire (Sangha, Stucki, Liang, Fossel, & Katz, 2003), which assesses the presence of
medical problems, their severity, and whether the condition limits functioning. Participants
received a maximum of 3 points for each medical condition (1 point for its presence, 1 point
if they received treatment for the condition, and 1 point if the condition limited activities).
There were 15 conditions and the option to add 3 additional conditions. The possible score
range was 0 to 54.
The Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire
(CPFQ) (Fava et al., 2006) is a 7-item measure of physical well-being and cognitive and
executive dysfunction. Each item uses a 6-point scale ranging from 1 (greater than normal)
to 6 (totally absent). The total score is the sum of items a to g, with a range of 7 to 42.
Higher scores indicate poorer functioning.

Author Manuscript

The Physical Health Status component score of the SF-36 (Ware, 2003) was used to assess
physical health. It is a weighted average of all of the subscale scores for Physical
Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, RoleEmotional, and Mental Health, with the Physical Functioning, Role-Physical, Bodily Pain,
and General Health subscales contributing the most. Higher scores indicate perceived better
health and functioning.
Data Analysis

Author Manuscript

Bivariate tests for race and ethnic differences at baseline were conducted using chi-square
and analysis of variance (ANOVA) for categorical and continuous outcomes, respectively.
Significant chi-square tests were followed by Bonferroni-corrected comparisons between
each pair of groups. Significant ANOVAs were followed by pair-wise comparisons using
the Tukey-Kramer test (results not shown and only significant pair-wise comparisons are
reported in the text). However, because this study is intended to characterize the sample
using a retrospective analysis of baseline data, no correction was made for the number of
outcomes examined.

Author Manuscript

Effect sizes were measured by omega-squared for continuous outcomes and Cramer’s V for
categorical outcomes. Omega-squared can be interpreted as an estimate of the percent of
population variance explained by group membership. Therefore, benchmarks from Cohen’s
d can be applied (Cohen, 1988) where small (d = 0.2), medium (d = 0.5), and large (d = 0.8)
effects account for 1%, 6%, and 14% of variance explained, respectively. Because Cramer’s
V can be interpreted as a correlation, we applied Cohen’s benchmarks for correlations and
regard Cramer’s V of 0.1, 0.3, and 0.5 as small, medium, and large, respectively.
Multivariate tests were produced by analysis of covariance (ANCOVA) controlling for age,
gender, and education.

RESULTS
Demographics and Drug Use
The baseline demographic and drug use characteristics for this treatment seeking sample of
stimulant abusers (N = 290) are presented in Table 1, stratified by race and ethnicity. Black
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participants were significantly older than Whites or Hispanics (p < .001). Hispanic
participants were more likely to have less education (p = .014). Gender also varied
significantly across race and ethnicity (p < .001).
Significant differences between groups were found on drug use characteristics. Black and
Hispanic participants were more likely to use alcohol (78.1% and 71.0%, respectively) than
White participants (55.0%) (p < .001). Blacks had higher rates of cocaine use (97.7%)
versus Whites (63.4%) or Hispanics (67.7%) (p < .001), but lower rates of
methamphetamine use (3.1%) than Hispanics (35.5%) and especially Whites (47.3%) (p < .
001). Whites had higher rates of other stimulant use (5.3%) than Blacks (0%) (p < .001).
Whites also used other illicit drugs (32.1%) at higher rates than Blacks (4.7%) and Hispanics
(9.7%) (p < .001).

Author Manuscript

Stimulant use diagnoses showed similar differences by race and ethnicity. Black participants
(91.4%) were more likely than Hispanics (51.6%) to be diagnosed with cocaine abuse or
dependence only, whereas Whites (28.5%) were least likely to have a cocaine only use
disorder. Whites (53.1%) and Hispanics (38.7%) were more likely than Blacks (5.5%) to be
diagnosed with both a cocaine and other stimulant use disorder, whereas Whites (18.5%)
were more likely than Hispanics (9.7%) and Blacks (3.1%) to be diagnosed with other
stimulant use disorder only. Blacks were significantly more likely to report smoking cocaine
(74.8%) than Whites (45.9%) or Hispanics (59.3).
Comorbid Mental Health and Physical Health Conditions

Author Manuscript

Table 2 describes comorbid conditions across race and ethnic groups, and related mental
health, physical health, and well-being. On measures of mental health, Black participants
endorsed fewer psychiatric disorders (mean = 0.7, standard deviation [SD] = 0.9, p = .002)
and symptoms of depression (mean = 4.2, SD = 2.4, p < .001) than Whites or Hispanics and
reported a lower risk for suicide (mean = 7.2, SD = 6.0, p = .008) than Whites. Black
participants reported better mental health status (mean = 47.0, SD = 11.4) than Hispanics
(mean = 40.0, SD = 13.4) and Whites (mean = 39.3, SD = 14.4, p < .001), as well as better
quality of life (mean = 72.7, SD = 14.5) than Whites (mean = 65.4, SD = 17.2).
Regarding physical health comorbidities (Table 2), Black participants reported poorer
physical health status (Blacks: mean = 53.5, SD = 7.6; Whites: mean = 56.2, SD = 6.8;
Hispanics: mean = 56.6, SD = 7.1; p = .005), and lower cognitive and physical functioning
than Whites (Blacks; mean = 16.0, SD = 4.9; Whites: mean = 19.6, SD = 7.1; Hispanics:
mean = 18.0, SD = 5.5; p < .001).

Author Manuscript

The results of the multivariate analysis are shown in Table 3. After adjusting for age,
gender, and education, findings for physical health status were no longer significant (p = .
373). All other significant findings remained.

DISCUSSION
In this large, heterogeneous sample of community-based treatment seeking stimulant
abusers, we found important differences between race and ethnic groups on several mental
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health, physical health, and wellness measures that could help identify potential areas for
intervention to improve treatment outcomes. White, Black, and Hispanic participants
reported varied demographic characteristics, substance use patterns and diagnoses, and
comorbid mental and physical health conditions. Effect sizes for ethnic differences on
demographic and substance abuse variables were relatively large compared to those
associated with comorbid conditions. Blacks were more likely to use alcohol and to be
diagnosed with a cocaine use disorder only, whereas Whites were more likely to use
methamphetamines and a variety of other illicit drugs and to be diagnosed with both a
cocaine and other stimulant use disorder or other stimulant use disorder only. Hispanics,
similar to Blacks, were more likely to use alcohol, but their rates of methamphetamine use
and diagnoses for cocaine and other stimulant use disorder or other stimulant use disorder
only fell in between Whites and Blacks.

Author Manuscript

These findings are consistent with other studies examining the relationship of race and
ethnicity to drug use across various settings. An aggregate investigation of self-reported
drug abuse and dependence from multiple National Household Surveys on Drug Abuse
showed that Blacks report higher rates of cocaine use by routes with faster absorption (i.e.,
smoking or injection), which are associated with higher rates of dependence (Chen &
Kandel, 2002). Nearly half of all cocaine-related emergency room episodes in the United
States in the past decade occurred among Blacks, significantly higher than any other race or
ethnic group (Chen & Kandel, 2002). Methamphetamine-positive patients in a trauma
setting were more likely to be White or Hispanic (Schermer & Wisner, 1999) and Blacks in
rural settings were less likely to use methamphetamine compared to Whites (Borders et al.,
2008), suggesting that our finding of more methamphetamine use among Whites and
Hispanics is not limited to this treatment-seeking population.

Author Manuscript

Blacks in this study reported fewer psychiatric disorders and symptoms of depression and
better mental health status and well-being, consistent with several large studies that found
lower rates of depression in Blacks compared to other groups (Jonas, Brody, Roper, &
Narrow, 2003; Kessler et al., 2003). These findings were unexpected given the higher rates
of reported physical comorbidities and cognitive difficulties observed in this group.
However, these findings are consistent with other data in which similar differences have
been attributed to a variety of reasons including underreporting despite using systematic
measures, differences in expression of depressive symptoms, or true differences in
prevalence (Alim, Charney, & Mellman, 2006). Underreporting may occur because Blacks
delay seeking help for mental health concerns or utilize informal behavioral health services
(K. Davis, 2011).

Author Manuscript

By contrast, Hispanics and Whites also appeared to have the greatest mental health needs,
with both reporting more psychiatric disorders and depressive symptoms and Whites
reporting more risk for suicide, although effect sizes were small. Methamphetamine abuse
predicts reduced mental health status (Vearrier, Greenberg, Miller, Okaneku, & Haggerty,
2012) and the reports of poor mental health in Whites and Hispanics in this study may be
associated with their greater use of methamphetamine, although a causal relationship cannot
be established. This is consistent with previous findings among mostly White
methamphetamine users in outpatient treatment who reported more past suicide attempts,
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had higher rates of mood disorders (primarily major depression), and were twice as likely to
be prescribed psychiatric medications compared to primary cocaine users (Copeland &
Sorensen, 2001).
In this study, Black participants reported more comorbid medical conditions, poorer health
status, and lower physical and cognitive functioning than other groups. These differences
may be explained by age differences at treatment entry (i.e., Blacks were older) and
correspond with previous research that found Black clients were least likely to initiate
substance abuse treatment (Acevedo et al., 2012). Alternative explanations may also include
barriers to services or poorer quality medical care for Blacks associated with, among other
factors, a general mistrust of medical providers that arises from historical persecution and
documented abuse and perceived mistreatment in health care settings because of racial
background (U.S. Department of Health and Human Services, 2001).

Author Manuscript

Physical health conditions could also be associated with the effects of cocaine or alcohol use
in Blacks and linked directly to the toxicity of each drug (Corrao, Bagnardi, Zambon, & La
Vecchia, 2004; Stein, 1999) or route of drug administration (e.g., smoking of crack cocaine)
(Winger, Woods, & Hofmann, 2004). However, explanations for race and ethnic differences
in physical health associated with drug of choice may be weaker than other possible
explanations because methamphetamine abusers (mostly White and Hispanic in this sample)
experience numerous medical conditions (Panenka et al., 2013) and cocaine and
methamphetamine use are both related to impaired cognitive functions (Simon et al., 2002).

Author Manuscript

There are limitations to this study that should be noted. The study was a retrospective
assessment of baseline substance abuse and mental and physical health measures collected.
Future studies should prospectively aim to better clarify the relationships between these
disorders, substance use, and comorbid conditions. In addition, the data are self-report,
which may be subject to recall bias, although the time periods assessed for most measures
were relatively short (7–30 days). The eligibility criteria were also somewhat restricted in
that individuals with physical issues or illnesses that would preclude exercise or those with
psychiatric safety concerns were not eligible, thus potentially restricting information on
physical and psychiatric health. Participants also had to be interested and willing to exercise,
which may reduce generalizability to the larger treatment-seeking population.

Author Manuscript

Alternatively, a major strength is that the data for this study come from a sample of
stimulant abusers seeking community-based addiction treatment across a geographically
diverse set of community treatment providers. Thus, results may generalize to a broader
clinical sample. This baseline study also adds to the current research literature because racial
and ethnic minority populations are underrepresented in clinical trials. There is less
information available about the treatment needs of minority groups, even more so for racial
and ethnic minority stimulant abusers. Racial and ethnic groups have different patterns of
substance use, which may impact their risk for comorbid mental and physical health
conditions, as well as their risk for relapse after treatment.
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CONCLUSION
Furthermore, these findings offer implications for stimulant abuse treatment. They highlight
the usefulness of integrating mental and physical health services into substance abuse
treatment programs serving racially and ethnically diverse patients. Receipt of primary
medical care is associated with lower addiction severity and suggests that efforts to link
treatment seeking substance abusers to primary medical care services should be considered
(Saitz, Horton, Larson, Winter, & Samet, 2005). Integrating mental and physical health care
into substance abuse treatment while paying attention to differences in racial and ethnic
groups, who have varying comorbid drug use, mental health, and medical needs, could have
a substantial impact on treatment outcomes.

Acknowledgments
Author Manuscript

Research reported in this publication was supported by the National Institute on Drug Abuse of the National
Institutes of Health under Award Number U10DA020024 (PI: Trivedi). The content is solely the responsibility of
the authors and does not necessarily represent the official views of the National Institutes of Health.

REFERENCES

Author Manuscript
Author Manuscript

Acevedo A, Garnick DW, Lee MT, Horgan CM, Ritter G, Panas L, Reynolds M. Racial and ethnic
differences in substance abuse treatment initiation and engagement. Journal of Ethnicity in
Substance Abuse. 2012; 11(1):1–21. [PubMed: 22381120]
Alim TN, Charney DS, Mellman TA. An overview of posttraumatic stress disorder in African
Americans. Journal of Clinical Psychology. 2006; 62:801–813. [PubMed: 16703601]
American College of Sports Medicine. ACSM’s Guidelines for Exercise Testing and Prescription. 8th.
Philadelphia, PA: Lippincott Williams & Wilkins; 2010.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IVTR. 4th. Washington, DC: American Psychiatric Association; 2000.
Arean PA, Alvidrez J, Nery R, Estes C, Linkins K. Recruitment and retention of older minorities in
mental health services research. The Gerontologist. 2003; 43(1):36–44. [PubMed: 12604744]
Borders TF, Booth BM, Han X, Wright P, Leukefeld C, Falck RS, Carlson RG. Longitudinal changes
in methamphetamine and cocaine use in untreated rural stimulant users: Racial differences and the
impact of methamphetamine legislation. Addiction. 2008; 103:800–808. [PubMed: 18412758]
Burlew AK, Feaster D, Brecht ML, Hubbard R. Measurement and data analysis in research addressing
health disparities in substance abuse. Journal of Substance Abuse Treatment. 2009; 36(1):25–43.
[PubMed: 18550320]
Burlew AK, Weekes JC, Montgomery L, Feaster DJ, Robbins MS, Rosa CL, Wu LT. Conducting
research with racial/ethnic minorities: Methodological lessons from the NIDA Clinical Trials
Network. The American Journal of Drug and Alcohol Abuse. 2011; 37:324–332. [PubMed:
21854274]
Carroll KM, Rosa CL, Brown LS Jr, Daw R, Magruder KM, Beatty LB. Addressing ethnic disparities
in drug abuse treatment in the Clinical Trials Network. Drug and Alcohol Dependence. 2007;
90:101–106.
Chang CK, Hayes RD, Broadbent M, Fernandes AC, Lee W, Hotopf M, Stewart R. All-cause mortality
among people with serious mental illness (SMI), substance use disorders, and depressive disorders
in southeast London: A cohort study. BMC Psychiatry. 2010; 10:77. [PubMed: 20920287]
Chen K, Kandel D. Relationship between extent of cocaine use and dependence among adolescents
and adults in the United States. Drug and Alcohol Dependence. 2002; 68:65–85. [PubMed:
12167553]
Cohen, J. Statistical power analysis for the behavioral sciences. 2nd. Mahwah, NJ: Lawrence Erlbaum;
1988.

J Ethn Subst Abuse. Author manuscript; available in PMC 2016 January 12.

Sanchez et al.

Page 11

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Compton WM, Cottler LB, Jacobs JL, Ben-Abdallah A, Spitznagel EL. The role of psychiatric
disorders in predicting drug dependence treatment outcomes. American Journal of Psychiatry.
2003; 160:890–895. [PubMed: 12727692]
Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity
of DSM-IV drug abuse and dependence in the United States - Results from the national
epidemiologic survey on alcohol and related conditions. Archives of General Psychiatry. 2007;
64:566–576. [PubMed: 17485608]
Copeland AL, Sorensen JL. Differences between methamphetamine users and cocaine users in
treatment. Drug and Alcohol Dependence. 2001; 62:91–95. [PubMed: 11173172]
Corrao G, Bagnardi V, Zambon A, La Vecchia C. A meta-analysis of alcohol consumption and the risk
of 15 diseases. Preventive Medicine. 2004; 38:613–619. [PubMed: 15066364]
Davis, K. Pathways to integrated health care: Strategies for African American communities and
organizations. Rockville, MD: United States Department of Health and Human Services, Office of
Minority Health; 2011.
Davis K, Schoenbaum SC, Audet AM. A 2020 vision of patient-centered primary care. Journal of
General Internal Medicine. 2005; 20:953–957. [PubMed: 16191145]
Davis LL, Pilkinton P, Wisniewski SR, Trivedi MH, Gaynes BN, Howland RH, Rush AJ. Effect of
concurrent substance use disorder on the effectiveness of single and combination antidepressant
medications for the treatment of major depression: An exploratory analysis of a single-blind
randomized trial. Depression and Anxiety. 2012; 29:111–122. [PubMed: 22495941]
De Alba I, Samet JH, Saitz R. Burden of medical illness in drug- and alcohol-dependent persons
without primary care. The American Journal on Addictions. 2004; 13(1):33–45. [PubMed:
14766436]
Druss BG, von Esenwein SA. Improving general medical care for persons with mental and addictive
disorders: Systematic review. General Hospital Psychiatry. 2006; 28:145–153. [PubMed:
16516065]
Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire:
A new measure. Psychopharmacology Bulletin. 1993; 29:321–326. [PubMed: 8290681]
Fava M, Graves LM, Benazzi F, Scalia MJ, Iosifescu DV, Alpert JE, Papakostas GI. A cross-sectional
study of the prevalence of cognitive and physical symptoms during long-term antidepressant
treatment. The Journal of Clinical Psychiatry. 2006; 67:1754–1759. [PubMed: 17196056]
Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K. The Fagerstrom test for nicotine
dependence: A revision of the Fagerstrom tolerance questionnaire. British Journal of Addiction.
1999; 86:1119–1127. [PubMed: 1932883]
Institute of Medicine. Unequal treatment: Confronting racial and ethnic disparities in health care.
Washington, DC: The National Academies Press; 2003.
Jonas BS, Brody D, Roper M, Narrow WE. Prevalence of mood disorders in a national sample of
young American adults. Social Psychiatry and Psychiatric Epidemiology. 2003; 38:618–624.
[PubMed: 14614549]
Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Wang PS. The epidemiology of
major depressive disorder - Results from the national comorbidity survey replication (NCS-R).
JAMA: The Journal of the American Medical Association. 2003; 289:3095–3105. [PubMed:
12813115]
Kozlowski LT, Porter CQ, Orleans CT, Pope MA, Heatherton T. Predicting smoking cessation with
self-reported measures of nicotine dependence: FTQ, FTND, and HSI. Drug and Alcohol
Dependence. 1994; 34:211–216. [PubMed: 8033758]
McLellan AT, Luborsky L, Woody GE, O’Brien CP. An improved diagnostic evaluation instrument
for substance abuse patients. The addiction severity index. The Journal of Nervous and Mental
Disease. 1980; 168(1):26–33. [PubMed: 7351540]
National Institue on Drug Abuse. Rockville, MD: NIDA; 2011. DrugFacts: Treatment statistics.
Retrieved from http://www.drugabuse.gov/publications/drugfacts/treatment-statistics
Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: A
meta-analysis. JAMA: The Journal of the American Medical Association. 2004; 291:1887–1896.
[PubMed: 15100209]

J Ethn Subst Abuse. Author manuscript; available in PMC 2016 January 12.

Sanchez et al.

Page 12

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Panenka WJ, Procyshyn RM, Lecomte T, MacEwan GW, Flynn SW, Honer WG, Barr AM.
Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings.
Drug and Alcohol Dependence. 2013; 129:167–179. [PubMed: 23273775]
Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Towle LH. The composite
international diagnostic interview. An epidemiologic instrument suitable for use in conjunction
with different diagnostic systems and in different cultures. Archives of General Psychiatry. 1988;
45:1069–1077. [PubMed: 2848472]
Saitz R, Horton NJ, Larson MJ, Winter M, Samet JH. Primary medical care and reductions in
addiction severity: A prospective cohort study. Addiction. 2005; 100:70–78. [PubMed: 15598194]
Saloner B, Le Cook B. Blacks and Hispanics are less likely than whites to complete addiction
treatment, largely due to socioeconomic factors. Health Affairs. 2013; 32:135–145. [PubMed:
23297281]
Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The self-administered comorbidity
questionnaire: A new method to assess comorbidity for clinical and health services research.
Arthritis & Rheumatism. 2003; 49:156–163. [PubMed: 12687505]
Schermer CR, Wisner DH. Methamphetamine use in trauma patients: A population-based study.
Journal of the American College of Surgeons. 1999; 189:442–449. [PubMed: 10549732]
Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Janavs J, Weiller E, Keskiner A, Dunbar GC. The
validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and
its reliability. European Psychiatry. 1997; 12:232–241.
Simon SL, Domier CP, Sim T, Richardson K, Rawson RA, Ling W. Cognitive performance of current
methamphetamine and cocaine abusers. Journal of Addictive Diseases. 2002; 21:61–74. [PubMed:
11831501]
Sobell, LC.; Sobell, MB. Timeline follow-back: A technique for assessing self-reported ethanol
consumption. In: Litten, RZ.; Allen, JP., editors. Measuring alcohol consumption: Psychosocial
and biological methods. Totowa, NJ: Humana Press; 1992. p. 41-72.
Stein MD. Medical consequences of substance abuse. The Psychiatric Clinics of North America. 1999;
22:351–370. [PubMed: 10385938]
Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS)
2005: Discharges from substance abuse treatment services. Rockville, MD: SAMHSA; 2008.
DASIS Series: S-41, DHHS Publication No. (SMA) 08–4314.
Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics
and Quality. Rockville, MD: SAMHSA; 2010. Results from the 2009 national survey on drug use
and health: Mental health findings. NSDUH Series H-39, HHS Publication No. SMA 10–4609.
Trivedi MH, Greer TL, Grannemann BD, Church TS, Somoza E, Blair SN, Nunes E. Stimulant
reduction intervention using dosed exercise (STRIDE) - CTN 0037: Study protocol for a
randomized controlled trial. Trials. 2011; 12:206. [PubMed: 21929768]
Trivedi MH, Wisniewski SR, Morris DW, Fava M, Gollan JK, Warden D, Rush AJ. Concise health
risk tracking scale: A brief self-report and clinician rating of suicidal risk. The Journal of Clinical
Psychiatry. 2011; 72:757–764. [PubMed: 21733476]
U.S. Department of Health and Human Services. Rockville, MD: Substance Abuse and Mental Health
Services Administration; 2001. Mental health: Culture, race, and ethnicity: A supplement to
mental health: A report to the surgeon general.
Vearrier D, Greenberg MI, Miller SN, Okaneku JT, Haggerty DA. Methamphetamine: History,
pathophysiology, adverse health effects, current trends, and hazards associated with the
clandestine manufacture of methamphetamine. Disease-a-Month. 2012; 58:38–89. [PubMed:
22251899]
Wadland WC, Ferenchick GS. Medical comorbidity in addictive disorders. The Psychiatric Clinics of
North America. 2004; 27:675–687. [PubMed: 15550287]
Warden D, Trivedi MH, Greer TL, Nunes E, Grannemann BD, Horigian VE, Szapocznik J. Rationale
and methods for site selection for a trial using a novel intervention to treat stimulant abuse.
Contemporary Clinical Trials. 2012; 33(1):29–37. [PubMed: 21946515]
Ware JE Jr. Conceptualization and measurement of health-related quality of life: Comments on an
evolving field. Arch Physical Medicine and Rehabilitation. 2003; 84(4 Suppl 2):S43–S51.

J Ethn Subst Abuse. Author manuscript; available in PMC 2016 January 12.

Sanchez et al.

Page 13

Author Manuscript

WHO. Geneva: World Health Organization; 1997. Composite International Diagnostic Interview
(CIDI core) version 2.1.
Winger, G.; Woods, JH.; Hofmann, FG. A handbook on drug and alcohol abuse: The biomedical
aspects. 4th. New York: Oxford University Press; 2004.
Wu LT, Blazer DG, Patkar AA, Stitzer ML, Wakim PG, Brooner RK. Heterogeneity of stimulant
dependence: A national drug abuse treatment clinical trials network study. The American Journal
on Addictions. 2009; 18:206–218. [PubMed: 19340639]
Yancey AK, Ortega AN, Kumanyika SK. Effective recruitment and retention of minority research
participants. Annual Review of Public Health. 2006; 27:1–28.

Author Manuscript
Author Manuscript
Author Manuscript
J Ethn Subst Abuse. Author manuscript; available in PMC 2016 January 12.

Author Manuscript

Author Manuscript
86 (29.7)

  Post High School

51 (17.6)

J Ethn Subst Abuse. Author manuscript; available in PMC 2016 January 12.
88 (30.4)
31 (10.7)

  Cocaine and stimulant abuse or dependence

  Stimulant (not cocaine) abuse or dependence

1 (0.4)
80 (30.4)
161 (61.2)

  Oral

  Nasal

  Smoking

Cocaine route of use

170 (58.8)

  Cocaine (not stimulant) abuse or dependence

Substance use disorders

  Other illicit drugs

7 (2.4)
125 (43.1)

  Other stimulants

  Marijuana

4 (1.4)

229 (79.0)

  Cocaine

77 (26.6)

194 (66.9)

  Alcohol

  Methamphetamine

10 (3.4)

  Other tobacco

  Amphetamine

225 (77.6)
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Substance use (past 30 days)

55 (19.0)
149 (51.4)

  High School graduate

115 (39.7)

n (%)

50 (45.9)

42 (38.5)

0 (0.0)

24 (18.5)

69 (53.1)

37 (28.5)

42 (32.1)

59 (45.0)

7 (5.3)

62 (47.3)

4 (3.1)

83 (63.4)

72 (55.0)

4 (3.1)

107 (81.7)

48 (36.6)

67 (51.1)

16 (12.2)

58 (44.3)

n (%)

35.5 (9.9)

M (SD)

M (SD)
39.1 (10.8)
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n = 131 (45%)

All
N = 290

  Less than High School

Education level

Female

Age (yrs)

Baseline
Characteristic

95 (74.8)

29 (22.8)

1 (0.8)

4 (3.1)

7 (5.5)

117 (91.4)

6 (4.7)

52 (40.6)

0 (0.0)

4 (3.1)

0 (0.0)

125 (97.7)

100 (78.1)

5 (3.9)

92 (71.9)

29 (22.7)

70 (54.7)

29 (22.7)

36 (28.1)

n (%)

44.1 (10.1)

M (SD)
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n = 128 (44%)
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9 (33.3)

s0 (0.0)

3 (9.7)
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16 (51.6)

3 (9.7)
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χ2/ F stat
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n = 128 (44%)

2 (7.4)

M (SD)
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n = 31 (11%)

χ2/ F stat
p-value

Effect Size

Note: Data are mean (standard deviation) or n (percentage); statistics were χ2 and F tests for categorical and continuous variables, respectively. Bolded information indicates group differences that were
significant at p < 0.05.
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42.8 (13.5)
68.8 (16.1)

Mental Health Status (SF-36)

Quality of Life (Q-LES-Q-SF)

Black
n = 128

65.4 (17.2)

39.3 (14.4)

19.6 (7.1)

1.0 (1.7)

3.9 (2.2)

56.2 (6.8)

9.6 (7.5)

6.3 (3.3)

1.2 (1.4)

72.7 (14.5)
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Effect Size

MINI: Mini International Neuropsychiatric Interview, QIDS-C: Quick Inventory of Depressive Symptomatology- Clinician Rated, CHRT-SR: Concise Health Risk Tracking-Self Report, SF-36: ShortForm Health Survey, FTND: Fagerstrom Test for Nicotine Dependence, SCQ: Self-Administered Comorbidity Questionnaire, CPFQ: Cognitive and Physical Functioning Questionnaire, Q-LES-Q-SF:
Quality of Life Enjoyment and Satisfaction Questionnaire Short Form.

Note: Data are mean (standard deviation); statistics were F tests for continuous variables. Bolded information indicates group differences that were significant at p < 0.05.
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4.0
1.2
19.8
39.3
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Nicotine Dependence (FTND)

No. of medical conditions (SCQ)

Cognitive and Physical Function (CPFQ)

Mental Health Status (SF-36)

Quality of Life (Q-LES-Q-SF)

74.0

47.1

15.7

1.2

3.0

54.4

6.8

4.2

0.6

Black
Mean

64.4

39.5

18.4

1.0

2.5

56.0

10.7

5.8

1.3

Hispanic
Mean

9.8

10.0

12.1

0.1

6.8

1.0

6.3

13.0
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F
stat
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0.000
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0.929

0.001

0.373
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0.001

p–
value

0.06
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0.07

−0.01

0.05

−0.00

0.04

0.07
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Effect
size

MINI: Mini International Neuropsychiatric Interview, QIDS-C: Quick Inventory of Depressive Symptomatology-Clinician Rated, CHRT-SR: Concise Health Risk Tracking- Self Report, SF-36: ShortForm Health Survey, FTND: Fagerstrom Test for Nicotine Dependence, SCQ: Self-Administered Comorbidity Questionnaire, CPFQ: Cognitive and Physical Functioning Questionnaire, Q-LES-Q-SF:
Quality of Life Enjoyment and Satisfaction Questionnaire Short Form.

Note: Data are means; statistics were F tests for continuous variables. Models adjusted for age, gender and education. Bolded information indicates group differences that were significant at p < 0.05.
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